临床病毒性脑炎标本的博尔纳病病毒核酸检测

目的 探讨临床病毒性脑炎(viral encephalitis,VE)患者与博尔纳病病毒(Borna disease virus,BDV)感染的关系,分析BDV感染的病毒性脑炎患者临床特征.方法 用荧光定量巢式逆转录聚合酶链反应(FQ-nRT-PCR)方法检测病毒性脑炎患者及非感染性疾病施行蛛网膜下腔阻滞麻醉的手术患者脑脊液单个核细胞(cerebrospinal fluid mononuclear cell,CSFMC)中BDV p24基因片段,同时用β-肌动蛋白(β-actin)作为内参照,脑脊液(CSF)阳性标本基因测序分析并总结出临床特征.结果 32例病毒性脑炎脑脊液标本BDV p24基因片段检出率为12.5%(4/32),拷贝数＞102/μl.对其中一份CSF阳性标本测序后,与BDV标准病毒株Ⅴ和马源的BDV病毒株H1766序列比较同源性分别为95.35%和98.84%.在4个位点出现基因突变(nt1649 T→C、nt1656 G→A、nt1670 C→T、nt1676 C→T).该目的基因片段与马源的BDV病毒株亲缘关系最近.阳性脑炎患者主要以精神行为异常为临床特征.结论 贵州省遵义市部分病毒性脑炎的发生与BDV感染有关,主要以精神行为异常为临床特征.     

重型肝炎中甲、乙型肝炎病毒合并感染的探讨

报告经血清免疫学抗HAVIgM、抗-HBcIgM、HBV-DNA、HBsAg/IgM复合物以及乙肝三种抗原抗体系统检测48例重型肝炎中甲、乙型肝炎病毒感染情况。结果:31例为HBV感染,1例为HAV感染,1例未定型,15例(31.25％)为甲、乙型合并感染(混合感染7例、重叠感染8例)。15例中亚急性10例、慢性5例;死亡或恶化10例,与同期“单纯”感染的重肝比较,包括主要临床生化指标均无显著差异。有7例患者病程中有近期出现“急黄肝”症状的历史,随后病情突然加重;1例发生在住院期间,且血清抗-HAVIgM转阳,最后死亡。认为合并感染可使部分急、慢性肝炎病情加重,甚至发展成重型。应注意发现。     

Active Case Finding of Current Bornavirus Infections in Human Encephalitis Cases of Unknown Etiology,Germany, 2018–2020

Human bornavirus encephalitis is a severe and often fatal infection caused by variegated squirrel bornavirus 1 (VSBV-1) and Borna disease virus 1 (BoDV-1). We conducted a prospective study of bornavirus etiology of encephalitis cases in Germany during 2018–2020 by using a serologic testing scheme applied along proposed graded case definitions for VSBV-1, BoDV-1, and unspecified bornavirus encephalitis. Of 103 encephalitis cases of unknown etiology, 4 bornavirus infections were detected serologically. One chronic case was caused by VSBV-1 after occupational-related contact of a person with exotic squirrels, and 3 acute cases were caused by BoDV-1 in virus-endemic areas. All 4 case-patients died. Bornavirus etiology could be confirmed by molecular methods. Serologic testing for these cases was virus specific, discriminatory, and a practical diagnostic option for living patients if no brain tissue samples are available. This testing should be guided by clinical and epidemiologic suspicions, such as residence in virus-endemic areas and animal exposure.     

56例极重型乙脑患者应用人工呼吸器治疗的并发症和死亡原因分析

对 5 6例使用机械通气的极重型乙脑患者的并发症和死亡原因进行分析。 5 6例患者呼吸衰竭的原因为 :脑水肿、脑疝 1 0例 ,呼吸道分泌物阻塞 8例 ,呼吸肌瘫痪 8例 ,混合因素 3 0例。应用机械通气后 5 6例患者中出现并发症的有 5 0例 (89.3 % )。机械通气 1 0d内仅 4例 (7.1 4% )发生感染 ,机械通气大于 2 0d有 48例 (85 .7% )发生感染(P <0 .0 1 ) ;同时机械通气大于 2 0d患者绿脓杆菌感染高达 2 7例 (4 8.2 % ) ,而机械通气小于 2 0d者仅 2例 (3 .6% )绿脓杆菌感染 (P <0 .0 1 )。结果提示 :极重型乙脑患者使用机械通气极易发生感染等并发症 ,通气天数减少 ,则并发症减少 ,病人存活机会增加。     

流行性乙型脑炎患者体内干扰素变化的临床意义

目的 :了解流行性乙型脑炎 (乙脑 )患者体内干扰素 (IFN)水平的变化。方法 :采用细胞病变抑制法 (CPE)检测5 1例乙脑患者血清及脑脊液 (CSF)中的IFN水平。结果 :(1)急性期血清及CSF中的IFN水平均显著升高 ,恢复期显著下降 ,但仍明显高于正常对照 ;CSF中的含量高于血液 ,并与病情的严重程度关系密切。 (2 )采用IFN肌肉注射治疗的患者用药后血清中IFN升高 ,但CSF中IFN水平未见升高 ,而且临床主要症状及体征改善与未用IFN组无显著差异。结论　 (1)IFN参与了乙型脑炎的发病过程。 (2 )IFN治疗并不能提高疗效 ,临床上不易贸然使用 ,需寻找其它更为有效的抗病毒治疗方法。     

乙型肝炎病毒相关肾炎临床与病毒血清学特点关联研究

目的 研究乙型肝炎病毒（HBV）感染与肾小球肾炎的关系,探讨HBV复制在HBV相关肾炎发病中的作用。方法 对338例经肾穿刺证实的肾炎患者的临床病理和病毒血清学特点进行分析。结果 HBV相关肾炎占肾炎总数的5．3％。在血HBsAg( )的肾炎患者中,HBV相关肾炎发病与HBeAg相关（P＜0．05）,与血清HBV DNA含量（bDNA)显著相关（P＜0．01）。分支链DNA（bDNA)阳性率明显高于HBeAg阳性率（P＜0．05）。结论 bDNA是反映HBV复制的最佳指标。HBV相关肾炎与体内HBV复制程度密切相关,HBV在体内大量复制,可能通过循环中的病毒抗原沉积于肾脏和肾脏中该抗原原位表达而致病。     

二羟丙腺苷加高压氧对小鼠脑炎病毒感染的抑制作用

目的 :研究S型与RS型二羟丙腺苷 (DHPA)与高压氧联用对人工感染小白鼠体内日本乙型脑炎 (乙脑 )病毒的抑制作用。方法 :整个实验用两株不同乙脑病毒分两次进行。每次一株 ,乙脑病毒接种小白鼠后将其分组 ,接种后 4～ 6h开始治疗 ,连续 5d ,于开始治疗后第二周末结束实验 ,计算每组小鼠死亡与存活数。结果 :对照组与 (S) DHPA/高压氧联合治疗组及 (RS) DHPA/高压氧联合治疗组效果差异有高度显著性 (P分别 <0 .0 2 5及 <0 .0 1) ,对照组与其他组治疗效果差异无显著性 (P均 >0 .0 5 )。结果 :(S) DHPA或 /及 (RS) DHPA与高压氧联合治疗可抑制人工感染小鼠体内日本乙型脑炎病毒的致病作用。     

Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers

Vaccinia virus has been used as a smallpox vaccine. Now that smallpox has been eradicated, the vaccinia virus is expected to be used as a bioterrorism countermeasure and a recombinant vaccine vector for other infectious diseases, such as viral hemorrhagic fevers. Many vaccinia virus strains were used as smallpox vaccines in the smallpox eradication campaign coordinated by the World Health Organization. These strains can be classified into generations, according to the history of improving production methods and efforts to reduce the adverse reactions. Significantly, the third-generation of smallpox vaccine strains, which include modified vaccinia Ankara (MVA) and LC16m8, are currently popular as recombinant vaccine vectors due to their well-balanced safety and immunogenicity profiles. The present review firstly focuses on the characteristics of the smallpox vaccine generations. The historical background of the development of the third-generation smallpox vaccine strains is detailed, along with the history of the transition of the vaccinia virus generation used as vectors for hemorrhagic fever vaccines to the third generation. Among the vaccinia viruses, MVA is currently the most commonly used vector for developing hemorrhagic fever vaccines, including dengue fever, yellow fever, Ebola viral disease, Lassa fever, Rift Valley fever, and Crimean-Congo hemorrhagic fever. LC16m8 is a vaccine candidate for severe fever with thrombocytopenia syndrome. The current status and recent advances in the development of these hemorrhagic fever vaccines using third-generation vaccinia strains are discussed.     

Applications of platform technologies in veterinary vaccinology and the benefits for one health

The animal-human interface has played a central role in advances made in vaccinology for the past two centuries. Many traditional veterinary vaccines were developed by growing, attenuating, inactivating and fractioning the pathogen of interest. While such approaches have been very successful, we have reached a point where they have largely been exhausted and alternative approaches are required. Furthermore, although subunit vaccines have enhanced safety profiles and created opportunities for combined discrimination between vaccinated and infected animal (DIVA) approaches, their functionality has largely been limited to diseases that can be controlled by humoral immunity until very recently. We now have a new generation of adjuvants and delivery systems that can elicit CD4 + T cells and/or CD8 +  T cell responses in addition to high-titre antibody responses. We review the current vaccine platform technologies, describe their roles in veterinary vaccinology and discuss how knowledge of their mode of action allows informed decisions on their deployment with wider benefits for One Health.